David Chang, Allogene CEO (Jeff Rumans)
Allogene hit with FDA clinical hold after a patient experiences 'abnormality' in CAR-T cells — shares hammered
The FDA has slapped a clinical hold on Allogene’s clinical trials after a patient in one of their early-stage studies for the off-the-shelf cell therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.